Find out more about our Academic Medical Centre and efforts in Academic Medicine
Academic Medicine Executive Committee (AM EXCO)
Find out more about what JOAM do to support AM initiatives
Find out more about the Office of Duke-NUS Affairs and Study Trip to Duke Durham
Guidelines, forms, and templates for Academic Medicine.
You should consider genetic testing if you or your family members meet one or more of the following criteria: 1. Sarcoma diagnosed before the age of 45 2. Sarcoma diagnosed at any age, with a relative diagnosed with cancer before the age of 45 or a sarcoma diagnosed at any age 3. Breast cancer diagnosed before the age of 31 4. A LFS-related condition* diagnosed before the age of 46 and a family history of cancer 5. Two or more LFS-related conditions* in the same individual 6. Two or more family members on the same side of the family with a LFS-related condition* before the age of 56 7. Adrenocortical cancer or rhabdomyosarcoma at any age 8. Tumour in the choroid plexus (membrane surrounding the brain) at any age 9. A previously identified faulty
TP53 gene in the family 10. A
TP53 gene fault identified at high frequency on tumour testing
While LFS may run in families, up to 25% of individuals with LFS may have acquired a faulty
TP53 gene at birth
(de novo). Therefore, genetic testing may also be offered in the absence of relevant family history and/or if an individual’s personal history is suspicious for LFS.
Personalised managementYour genetic test result may confirm whether your personal and/or family history is due to a hereditary condition like LFS, and clarify what your lifetime cancer risks may be. This information can be useful for doctors to personalise your medical care to help manage or reduce cancer risks.
If you have a cancer diagnosis
If you are currently cancer-free
Familial implicationsYour genetic test result can also help you understand if other family members are at risk of LFS. They can subsequently consider their own testing (predictive testing) to clarify their carrier status to determine tumour and cancer risks.Family members who
have inherited the same faulty
TP53 gene may be at increased risk of tumours and cancer and can benefit from management options such as screening (to detect tumours and cancer at an early and manageable stage) or surgery (to reduce their risk of cancer).Family members who
did not inherit the faulty
TP53 gene can avoid unnecessary screening and worry. Their children will also not be at risk.